Preliminary evidence for an involvement of the cholinergic system in the sedative effects of rolipram in rats

Pharmacology Biochemistry and Behavior

Volumn 64, Issue 1, 1999, Pages 1-5

  Silvestre, Jordi S ^a   Fernández, Andrés G ^a   Palacios, José M ^a  

^a Res Ctr Almirall Prodesfarma C ^*  (Spain)

Author keywords

Acetylcholine; Behavior; Locomotor activity; Open field; Physostigmine; Rat; Rolipram; Scopolamine; Sedation

Indexed keywords

CYCLIC AMP; PHOSPHODIESTERASE INHIBITOR; PHYSOSTIGMINE; ROLIPRAM; SCOPOLAMINE;

ANIMAL MODEL; ARTICLE; BEHAVIOR; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REARING; SEDATION; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

ACETYLCHOLINE; ANIMALS; CHOLINESTERASE INHIBITORS; EXPLORATORY BEHAVIOR; HYPNOTICS AND SEDATIVES; MALE; MOTOR ACTIVITY; MUSCARINIC ANTAGONISTS; PARASYMPATHETIC NERVOUS SYSTEM; PHYSOSTIGMINE; PYRROLIDINONES; RATS; RATS, WISTAR; ROLIPRAM; SCOPOLAMINE;

EID: 0345192302     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00243-3     Document Type: Article

References (32)

1. Asanuma M., Ogawa N., Kondo Y., Hirata H., Mori A. Effects of repeated administration of rolipram, a cAMP-specific phosphodiesterase inhibitor, on acetylcholinergic indices in the aged rat brain. Arch. Gerontol. Geriatr. 16:1993;191-198.
2. Bobon D., Breulet M., Gerard-Vandenhove M.-A., Guiot-Goffioul F., Plomteux G., Sastre-y-Hernández M., Schratzer M., Troisfontaines B., von Frenckell R., Wachtel H. Is phosphodiesterase inhibition a new mechanism of antidepressant action? Eur. Arch. Psychiatry Neurol. Sci. 238:1988;2-6.
3. DeBelleroche J., Bradford H.F. Biochemical evidence for the presence of presynaptic receptors on dopaminergic terminals. Brain Res. 142:1978;53-68.
4. Eckmann F., Fichte K., Meya U., Sastre-y-Hernández M. Rolipram in major depression. Results of a double-blind comparative study with amitriptyline Curr. Ther. Res. 43:1988;291-295.
5. Egawa T., Mishima K., Matsumoto Y., Iwasaki K., Fujiwara M. Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn. J. Pharmacol. 75:1997;275-281.
6. Fu W.M. Potentiation of acetylcholine responses in Xenopus embryonic muscle cells by dibutyryl cAMP. Pflugers Arch. 425:1993;439-445.
7. Griebel G., Misslin R., Vogel E., Bourguingnon J.-J. Behavioral effects of rolipram and structurally related compounds in mice. Behavioral sedation of cAMP phosphodiesterase inhibitors Pharmacol. Biochem. Behav. 39:1991;321-323.
8. Imanishi T., Sawa A., Ichumaru Y., Miyashiro M., Kato S., Yamamoto T., Ueki S. Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. Eur. J. Pharmacol. 321:1997;273-278.
9. Iyo M.M.D., Maeda Y., Inada T., Kitao Y., Sasaki H., Fukui S. The effects of a selective cAMP phosphodiesterase inhibitor, rolipram, on methamphetamine-induced behavior. Neuropsychopharmacology. 13:1995;33-39.
10. Katsura M., Kuriyama K. Effects of [1,3-di-n-butyl-7-(2-oxopropyl)-xanthine] denbufylline), a low Km phosphodiesterase inhibitor, on striatal acetylcholine release in the rat. Analysis using cerebral microdialysis Jpn. J. Pharmacol. 54:1990;441-446.
11. 3H]rolipram. Brain Res. 503:1989;229-245.
12. Kehr W., Debus G., Neumeister R. Effects of rolipram, a novel antidepressant on monoamine metabolism in rat brain. J. Neural. Transm. 63:1985;1-12.
13. Nicholson C.D. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology (Berlin). 101:1990;147-159.
14. Nicholson C.D., Challis R.A.J., Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci. 12:1991;19-27.
15. O'Neill M.F., Fernández A.G., Gristwood R.W., Palacios J.M. Mecamylamine reverses physostigmine-induced attenuation of scopolamine-induced hyperactivity. J. Neural Transm. 96:1994;9-18.
16. Porsolt, R. D.; Lenägre, A.; McArthur, R. A.: Pharmacological models of depression. In: Animal models in psychopharmacology: Advances in pharmacological sciences. Basel: Birkhñuser Verlag; 1991:137-159.
17. Przegalinski E., Bigajska K., Lewandowska A. The influence of rolipram on the central serotonergic system. Pharmacopsychiatria. 14:1981;162-166.
18. Randt C.T., Judge M.E., Bonnet K.A., Quartermain D. Brain cyclic AMP and memory in mice. Pharmacol. Biochem. Behav. 17:1982;677-680.
19. Sanberg P.R., Henault M.A., Hagenmeyer-Houser S.H., Russell K.H. The topography of amphetamine and scopolamine-induced hyperactivity. Toward an activity print Behav. Neurosci. 101:1987;131-133.
20. Schmiechen R., Schneider H.H., Wachtel H. Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology (Berlin). 102:1990;17-20.
21. Schneider H.H. Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation. Biochem. Pharmacol. 33:1984;1690-1693.
22. Schneider H.H., Schmiechen R., Brezinski M., Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol. 127:1986;105-115.
23. Schneider H.H., Yamaguchi M., Andrews J.S., Stephens D.N. Discriminative stimulus properties of the stereoisomers of the phosphodiesterase inhibitor rolipram. Pharmacol. Biochem. Behav. 50:1995;211-217.
24. Shannon H.E., Peters S.C. A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice. J. Pharmacol. Exp. Ther. 255:1990;549-553.
25. Smith D.F. Effects of lithium and rolipram enantiomers on locomotor activity in inbred mice. Pharmacol. Toxicol. 66:1990;142-145.
26. Torphy T.J., Stadel J.M., Burman M., Cieslinski L.B., McLaughlin M.M., White J.R., Livi G.P. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J. Biol. Chem. 267:1992;1798-1804.
27. Wachtel H. Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology (Berlin). 77:1982;309-316.
28. Wachtel H. Neurotropic effects of the optical isomers of the selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo. J. Pharm. Pharmacol. 35:1983;440-444.
29. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology. 22:1983;267-272.
30. Wachtel H. The second-messenger dysbalance hypothesis of affective disorders. Pharmacopsychiatry. 23:1990;27-32.
31. Wachtel H., Schneider H.H. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology. 25:1986;1119-1126.
32. Yeomans J.S. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology. 12:1995;3-16.